ENTO Profile
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing innovative therapies for gastrointestinal diseases. The company's research and development efforts are directed at creating targeted and non-systemic treatments that address various unmet medical needs in the field of gastroenterology. Entero Therapeutics is committed to advancing its proprietary technologies and therapeutic candidates through clinical trials to offer new solutions for patients suffering from complex digestive disorders.
Among its key product candidates, Entero Therapeutics is advancing latiglutenase, an oral biotherapeutic designed to manage celiac disease. This therapy aims to break down gluten into non-immunogenic peptides, potentially mitigating the adverse immune response associated with gluten consumption. Another significant candidate is adrulipase, a recombinant lipase enzyme engineered to assist in the digestion of fats and other nutrients, offering a potential breakthrough for patients with pancreatic insufficiency.
The company's pipeline also includes capeserod, a selective 5-HT4 receptor partial agonist under development for the treatment of gastroparesis, a condition characterized by delayed gastric emptying. Additionally, Entero Therapeutics is exploring the use of niclosamide, an oral small molecule with anti-inflammatory properties, for managing inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. The company is also working on CypCel, a disease management tool designed to monitor intestinal health in recovering celiac disease patients, enhancing the overall management of the condition.
Founded in 2014 and formerly known as AzurRx BioPharma, Inc., Entero Therapeutics rebranded to its current name in September 2021. Headquartered in Boca Raton, Florida, the company continues to leverage its expertise in gastrointestinal therapeutics to develop novel treatments that improve patient outcomes and address critical gaps in current medical practice.
|
